

Therapies and Diagnostics for Ovarian Cancer Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/TA912895625BEN.html>

Date: February 2022

Pages: 65

Price: US\$ 3,250.00 (Single User License)

ID: TA912895625BEN

Abstracts

Ovarian cancer (ovarian cancer) accounts for 2.4% ~ 6.5% of the common malignant tumors in women, and ranks the third among the cancers of the female reproductive system, secondary to cervical cancer and uterine body cancer. In recent years, due to the prevention and treatment of cervical cancer and uterine body cancer, some achievements have been made, while the prevention and treatment of ovarian cancer is relatively small. So ovarian cancer is the leading cause of death among cancers of the reproductive system in women.

This report contains market size and forecasts of Therapies and Diagnostics for Ovarian Cancer in Global, including the following market information:

Global Therapies and Diagnostics for Ovarian Cancer Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Therapies and Diagnostics for Ovarian Cancer market was valued at 2055 million in 2021 and is projected to reach US\$ 2673 million by 2028, at a CAGR of 3.8% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Surgery Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Therapies and Diagnostics for Ovarian Cancer include

Astra Zeneca, Clovis Oncology, Myriad, TESARO, AbbVie Inc, Celgene, Janssen Pharmaceuticals, Merck and Novartis AG and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Therapies and Diagnostics for Ovarian Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Therapies and Diagnostics for Ovarian Cancer Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Therapies and Diagnostics for Ovarian Cancer Market Segment Percentages, by Type, 2021 (%)

Surgery

Radiation Therapy

Drug Treatment

Global Therapies and Diagnostics for Ovarian Cancer Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Therapies and Diagnostics for Ovarian Cancer Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Others

Global Therapies and Diagnostics for Ovarian Cancer Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Therapies and Diagnostics for Ovarian Cancer Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Therapies and Diagnostics for Ovarian Cancer revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Therapies and Diagnostics for Ovarian Cancer revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Astra Zeneca

Clovis Oncology

Myriad

TESARO

AbbVie Inc

Celgene

Janssen Pharmaceuticals

Merck

Novartis AG

Quest Diagnostics Inc

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Therapies and Diagnostics for Ovarian Cancer Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Therapies and Diagnostics for Ovarian Cancer Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER OVERALL MARKET SIZE

- 2.1 Global Therapies and Diagnostics for Ovarian Cancer Market Size: 2021 VS 2028
- 2.2 Global Therapies and Diagnostics for Ovarian Cancer Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Therapies and Diagnostics for Ovarian Cancer Players in Global Market
- 3.2 Top Global Therapies and Diagnostics for Ovarian Cancer Companies Ranked by Revenue
- 3.3 Global Therapies and Diagnostics for Ovarian Cancer Revenue by Companies
- 3.4 Top 3 and Top 5 Therapies and Diagnostics for Ovarian Cancer Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Therapies and Diagnostics for Ovarian Cancer Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Therapies and Diagnostics for Ovarian Cancer Players in Global Market
 - 3.6.1 List of Global Tier 1 Therapies and Diagnostics for Ovarian Cancer Companies

3.6.2 List of Global Tier 2 and Tier 3 Therapies and Diagnostics for Ovarian Cancer Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Therapies and Diagnostics for Ovarian Cancer Market Size Markets, 2021 & 2028

4.1.2 Surgery

4.1.3 Radiation Therapy

4.1.4 Drug Treatment

4.2 By Type - Global Therapies and Diagnostics for Ovarian Cancer Revenue & Forecasts

4.2.1 By Type - Global Therapies and Diagnostics for Ovarian Cancer Revenue, 2017-2022

4.2.2 By Type - Global Therapies and Diagnostics for Ovarian Cancer Revenue, 2023-2028

4.2.3 By Type - Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Therapies and Diagnostics for Ovarian Cancer Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Others

5.2 By Application - Global Therapies and Diagnostics for Ovarian Cancer Revenue & Forecasts

5.2.1 By Application - Global Therapies and Diagnostics for Ovarian Cancer Revenue, 2017-2022

5.2.2 By Application - Global Therapies and Diagnostics for Ovarian Cancer Revenue, 2023-2028

5.2.3 By Application - Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Therapies and Diagnostics for Ovarian Cancer Market Size, 2021 & 2028

6.2 By Region - Global Therapies and Diagnostics for Ovarian Cancer Revenue & Forecasts

6.2.1 By Region - Global Therapies and Diagnostics for Ovarian Cancer Revenue, 2017-2022

6.2.2 By Region - Global Therapies and Diagnostics for Ovarian Cancer Revenue, 2023-2028

6.2.3 By Region - Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Therapies and Diagnostics for Ovarian Cancer Revenue, 2017-2028

6.3.2 US Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.3.3 Canada Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.3.4 Mexico Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Therapies and Diagnostics for Ovarian Cancer Revenue, 2017-2028

6.4.2 Germany Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.4.3 France Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.4.4 U.K. Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.4.5 Italy Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.4.6 Russia Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.4.7 Nordic Countries Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.4.8 Benelux Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Therapies and Diagnostics for Ovarian Cancer Revenue, 2017-2028

6.5.2 China Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.5.3 Japan Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.5.4 South Korea Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.5.5 Southeast Asia Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.5.6 India Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Therapies and Diagnostics for Ovarian Cancer

Revenue, 2017-2028

6.6.2 Brazil Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.6.3 Argentina Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue, 2017-2028

6.7.2 Turkey Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.7.3 Israel Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.7.4 Saudi Arabia Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

6.7.5 UAE Therapies and Diagnostics for Ovarian Cancer Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Astra Zeneca

7.1.1 Astra Zeneca Corporate Summary

7.1.2 Astra Zeneca Business Overview

7.1.3 Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Major Product Offerings

7.1.4 Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Revenue in Global Market (2017-2022)

7.1.5 Astra Zeneca Key News

7.2 Clovis Oncology

7.2.1 Clovis Oncology Corporate Summary

7.2.2 Clovis Oncology Business Overview

7.2.3 Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Major Product Offerings

7.2.4 Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Revenue in Global Market (2017-2022)

7.2.5 Clovis Oncology Key News

7.3 Myriad

7.3.1 Myriad Corporate Summary

7.3.2 Myriad Business Overview

7.3.3 Myriad Therapies and Diagnostics for Ovarian Cancer Major Product Offerings

7.3.4 Myriad Therapies and Diagnostics for Ovarian Cancer Revenue in Global Market (2017-2022)

7.3.5 Myriad Key News

7.4 TESARO

- 7.4.1 TESARO Corporate Summary
- 7.4.2 TESARO Business Overview
- 7.4.3 TESARO Therapies and Diagnostics for Ovarian Cancer Major Product Offerings
- 7.4.4 TESARO Therapies and Diagnostics for Ovarian Cancer Revenue in Global Market (2017-2022)
- 7.4.5 TESARO Key News
- 7.5 AbbVie Inc
 - 7.5.1 AbbVie Inc Corporate Summary
 - 7.5.2 AbbVie Inc Business Overview
 - 7.5.3 AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Major Product Offerings
 - 7.5.4 AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Revenue in Global Market (2017-2022)
 - 7.5.5 AbbVie Inc Key News
- 7.6 Celgene
 - 7.6.1 Celgene Corporate Summary
 - 7.6.2 Celgene Business Overview
 - 7.6.3 Celgene Therapies and Diagnostics for Ovarian Cancer Major Product Offerings
 - 7.6.4 Celgene Therapies and Diagnostics for Ovarian Cancer Revenue in Global Market (2017-2022)
 - 7.6.5 Celgene Key News
- 7.7 Janssen Pharmaceuticals
 - 7.7.1 Janssen Pharmaceuticals Corporate Summary
 - 7.7.2 Janssen Pharmaceuticals Business Overview
 - 7.7.3 Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Major Product Offerings
 - 7.7.4 Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Revenue in Global Market (2017-2022)
 - 7.7.5 Janssen Pharmaceuticals Key News
- 7.8 Merck
 - 7.8.1 Merck Corporate Summary
 - 7.8.2 Merck Business Overview
 - 7.8.3 Merck Therapies and Diagnostics for Ovarian Cancer Major Product Offerings
 - 7.8.4 Merck Therapies and Diagnostics for Ovarian Cancer Revenue in Global Market (2017-2022)
 - 7.8.5 Merck Key News
- 7.9 Novartis AG
 - 7.9.1 Novartis AG Corporate Summary
 - 7.9.2 Novartis AG Business Overview

7.9.3 Novartis AG Therapies and Diagnostics for Ovarian Cancer Major Product Offerings

7.9.4 Novartis AG Therapies and Diagnostics for Ovarian Cancer Revenue in Global Market (2017-2022)

7.9.5 Novartis AG Key News

7.10 Quest Diagnostics Inc

7.10.1 Quest Diagnostics Inc Corporate Summary

7.10.2 Quest Diagnostics Inc Business Overview

7.10.3 Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Major Product Offerings

7.10.4 Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Revenue in Global Market (2017-2022)

7.10.5 Quest Diagnostics Inc Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Therapies and Diagnostics for Ovarian Cancer Market Opportunities & Trends in Global Market
- Table 2. Therapies and Diagnostics for Ovarian Cancer Market Drivers in Global Market
- Table 3. Therapies and Diagnostics for Ovarian Cancer Market Restraints in Global Market
- Table 4. Key Players of Therapies and Diagnostics for Ovarian Cancer in Global Market
- Table 5. Top Therapies and Diagnostics for Ovarian Cancer Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Therapies and Diagnostics for Ovarian Cancer Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Therapies and Diagnostics for Ovarian Cancer Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Therapies and Diagnostics for Ovarian Cancer Product Type
- Table 9. List of Global Tier 1 Therapies and Diagnostics for Ovarian Cancer Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Therapies and Diagnostics for Ovarian Cancer Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Therapies and Diagnostics for Ovarian Cancer Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - Therapies and Diagnostics for Ovarian Cancer Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - Therapies and Diagnostics for Ovarian Cancer Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - Therapies and Diagnostics for Ovarian Cancer Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), 2017-2022
- Table 19. By Region - Global Therapies and Diagnostics for Ovarian Cancer Revenue

(US\$, Mn), 2023-2028

Table 20. By Country - North America Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2023-2028

Table 30. Astra Zeneca Corporate Summary

Table 31. Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Product Offerings

Table 32. Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), (2017-2022)

Table 33. Clovis Oncology Corporate Summary

Table 34. Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Product Offerings

Table 35. Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), (2017-2022)

Table 36. Myriad Corporate Summary

Table 37. Myriad Therapies and Diagnostics for Ovarian Cancer Product Offerings

Table 38. Myriad Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), (2017-2022)

Table 39. TESARO Corporate Summary

Table 40. TESARO Therapies and Diagnostics for Ovarian Cancer Product Offerings

Table 41. TESARO Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), (2017-2022)

Table 42. AbbVie Inc Corporate Summary

Table 43. AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Product Offerings

Table 44. AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), (2017-2022)

Table 45. Celgene Corporate Summary

Table 46. Celgene Therapies and Diagnostics for Ovarian Cancer Product Offerings

Table 47. Celgene Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), (2017-2022)

Table 48. Janssen Pharmaceuticals Corporate Summary

Table 49. Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Product Offerings

Table 50. Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), (2017-2022)

Table 51. Merck Corporate Summary

Table 52. Merck Therapies and Diagnostics for Ovarian Cancer Product Offerings

Table 53. Merck Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), (2017-2022)

Table 54. Novartis AG Corporate Summary

Table 55. Novartis AG Therapies and Diagnostics for Ovarian Cancer Product Offerings

Table 56. Novartis AG Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), (2017-2022)

Table 57. Quest Diagnostics Inc Corporate Summary

Table 58. Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Product Offerings

Table 59. Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Therapies and Diagnostics for Ovarian Cancer Segment by Type in 2021

Figure 2. Therapies and Diagnostics for Ovarian Cancer Segment by Application in 2021

Figure 3. Global Therapies and Diagnostics for Ovarian Cancer Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Therapies and Diagnostics for Ovarian Cancer Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Therapies and Diagnostics for Ovarian Cancer Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Therapies and Diagnostics for Ovarian Cancer Revenue in 2021

Figure 8. By Type - Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

Figure 9. By Application - Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

Figure 10. By Region - Global Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

Figure 11. By Country - North America Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

Figure 12. US Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

Figure 16. Germany Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 17. France Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

Figure 24. China Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 28. India Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

Figure 30. Brazil Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Therapies and Diagnostics for Ovarian Cancer Revenue Market Share, 2017-2028

Figure 33. Turkey Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Therapies and Diagnostics for Ovarian Cancer Revenue, (US\$, Mn), 2017-2028

Figure 37. Astra Zeneca Therapies and Diagnostics for Ovarian Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Clovis Oncology Therapies and Diagnostics for Ovarian Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Myriad Therapies and Diagnostics for Ovarian Cancer Revenue Year Over

Year Growth (US\$, Mn) & (2017-2022)

Figure 40. TESARO Therapies and Diagnostics for Ovarian Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. AbbVie Inc Therapies and Diagnostics for Ovarian Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Celgene Therapies and Diagnostics for Ovarian Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Janssen Pharmaceuticals Therapies and Diagnostics for Ovarian Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Merck Therapies and Diagnostics for Ovarian Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Novartis AG Therapies and Diagnostics for Ovarian Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Quest Diagnostics Inc Therapies and Diagnostics for Ovarian Cancer Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Therapies and Diagnostics for Ovarian Cancer Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/TA912895625BEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TA912895625BEN.html>